NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Sure, and if that were the reason, and it was not fully disclosed, and the way the company would know is with an unblinded DSM review, which did not occur, but they’d need to announce that because they and ultimately if not them, then the regulators, would have to make such an incredibly important detail public, so too would it have been covered in the journal article and in the 80 page dismissal judgment that dismissed the lawsuit, though if it were true, it probably would not have been dismissed, and would have been a material fact that certainly would have come out somewhere else, and not even in an SEC investigation, then certainly in the record that the judge described. And if the company did not disclose it there, to the judge even, then that would be a serious concern.

I don’t think it is remotely possible that is the reason for the partial halt or the short number of patients being concentrated with the placebo arm when patients are supposed to be randomized.

And I definitely do not think they’d have received that big award in the UK if they were halted for that reason nor that prior to unblinding and approval they’d be able to sell at full cost, to UK citizens and visitors, DCVax-L. That would be a serious problem.

Dr. Liau does have a paper and protocol
For determining pseudoprogression from real progression, so I am not sure it is correct that was never resolved, and with that so too would a halt due to that have been lifted as well. They had an early progressor and pseudoprogressor special open label and compassionate arm. Those patients also did better than SOC as I recall.